JP2017532378A5 - - Google Patents

Download PDF

Info

Publication number
JP2017532378A5
JP2017532378A5 JP2017538918A JP2017538918A JP2017532378A5 JP 2017532378 A5 JP2017532378 A5 JP 2017532378A5 JP 2017538918 A JP2017538918 A JP 2017538918A JP 2017538918 A JP2017538918 A JP 2017538918A JP 2017532378 A5 JP2017532378 A5 JP 2017532378A5
Authority
JP
Japan
Prior art keywords
phospholipid
polymer
liposome composition
aromatic
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017538918A
Other languages
English (en)
Japanese (ja)
Other versions
JP6505235B2 (ja
JP2017532378A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/054732 external-priority patent/WO2016057812A1/en
Publication of JP2017532378A publication Critical patent/JP2017532378A/ja
Publication of JP2017532378A5 publication Critical patent/JP2017532378A5/ja
Application granted granted Critical
Publication of JP6505235B2 publication Critical patent/JP6505235B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017538918A 2014-10-08 2015-10-08 リポソームを用いるアミロイド斑のｍｒｉイメージング Active JP6505235B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201462061514P 2014-10-08 2014-10-08
US62/061,514 2014-10-08
US201562111057P 2015-02-02 2015-02-02
US62/111,057 2015-02-02
PCT/US2015/054732 WO2016057812A1 (en) 2014-10-08 2015-10-08 Mri imaging of amyloid plaque using liposomes

Publications (3)

Publication Number Publication Date
JP2017532378A JP2017532378A (ja) 2017-11-02
JP2017532378A5 true JP2017532378A5 (enExample) 2018-11-22
JP6505235B2 JP6505235B2 (ja) 2019-04-24

Family

ID=55653789

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017538918A Active JP6505235B2 (ja) 2014-10-08 2015-10-08 リポソームを用いるアミロイド斑のｍｒｉイメージング

Country Status (10)

Country Link
US (4) US9744251B2 (enExample)
EP (3) EP3204051B1 (enExample)
JP (1) JP6505235B2 (enExample)
KR (1) KR102409017B1 (enExample)
CN (1) CN107106708B (enExample)
AU (2) AU2015330824A1 (enExample)
CA (1) CA2963941C (enExample)
ES (2) ES3032054T3 (enExample)
MX (1) MX371295B (enExample)
WO (1) WO2016057812A1 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2012239888B9 (en) 2011-04-06 2017-10-12 Alzeca Biosciences, LLC Lipid-based nanoparticles
JP6130401B2 (ja) 2012-01-20 2017-05-17 アンナプラガダ，アナンス 医学画像を客観的に特徴付けるための方法および組成物
KR102409017B1 (ko) 2014-10-08 2022-06-16 텍사스 칠드런스 하스피탈 리포좀을 이용한 아밀로이드 플라크의 mri 영상화
JP7059270B2 (ja) 2016-07-22 2022-04-25 エーシー・イミューン・エス・アー タウタンパク質凝集体を画像化するための化合物
IL264239B (en) 2016-07-22 2022-08-01 Ac Immune Sa Compounds for imaging tau protein aggregates
EP3512570B1 (en) * 2016-09-16 2024-08-28 Texas Children's Hospital Liposomal gadolinium (gd) contrast agent for t1-mri
WO2018100540A1 (en) * 2016-11-30 2018-06-07 Texas Children's Hospital Hydrophilic fluorinated molecules for liposomal 19f mri probes with unique mr signatures
EP3743426A1 (en) 2018-01-24 2020-12-02 AC Immune SA Azacarboline compounds for the detection of tau aggregates
EP3743423A1 (en) 2018-01-24 2020-12-02 AC Immune SA Gamma-carboline compounds for the detection of tau aggregates
AU2019243579B2 (en) * 2018-03-29 2024-05-09 Microvascular Therapeutics LLC Compositions and methods of detecting and treating Alzheimer's disease
ES2988770T3 (es) 2018-06-08 2024-11-21 Ac Immune Sa Nuevos compuestos para diagnóstico
WO2020154623A1 (en) * 2019-01-24 2020-07-30 Alzeca Biosciences, LLC Functionalized liposomes for imaging misfolded proteins
EP3997244A4 (en) * 2019-07-08 2023-11-08 Alzeca Biosciences, Llc TARGETED LIGANDS FOR TAU PATHOLOGY
US11614451B2 (en) 2019-07-08 2023-03-28 Alzeca Biosciences, LLC Targeting ligands for tau pathology
US11116854B2 (en) * 2020-01-29 2021-09-14 Texas Children's Hospital Targeted contrast agents for MRI of amyloid deposition
CN115279424A (zh) * 2020-02-12 2022-11-01 德克萨斯儿童医院 用于α-突触核蛋白沉积MRI的靶向对比剂
US11779664B2 (en) 2020-02-12 2023-10-10 Texas Children's Hospital Targeted contrast agents for MRI of alpha-synuclein deposition
CN115970009A (zh) * 2023-02-08 2023-04-18 丽水市中心医院 Vhpk多肽修饰的荧光纳米脂质体给药系统、其制备方法及应用
CN116869938A (zh) * 2023-07-26 2023-10-13 安徽医科大学 一种1,2,4-噁二唑-吡啶脂质体及其制备方法和应用

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5204085A (en) 1985-01-08 1993-04-20 Mallinckrodt Medical, Inc. Method for enhancing the safety of metal-ligand chelates as X-ray contrast agents
ZA952485B (en) 1994-03-28 1995-12-15 Nycomed Imaging As Liposomes
US6071532A (en) * 1996-10-15 2000-06-06 Emory University Synthesis of glycophospholipid and peptide-phospholipid conjugates and uses thereof
ATE287700T1 (de) 1999-11-30 2005-02-15 Univ Arizona Strahlung-sensitive liposomen
WO2002028441A2 (en) 2000-10-04 2002-04-11 California Institute Of Technology Magnetic resonance imaging agents for in vivo labeling and detection of amyloid deposits
WO2002094191A2 (en) 2001-05-23 2002-11-28 New York University Detection of alzheimer's amyloid by magnetic resonance imaging
JP2005519129A (ja) 2002-03-05 2005-06-30 クリーブランド ステート ユニバーシティー エアロゾル薬物送達のための凝集粒子
WO2004096120A2 (en) * 2003-05-01 2004-11-11 Nst Neurosurvival Technologies Ltd. Compounds that selectively bind to membranes of apoptotic cells
US7208174B2 (en) 2003-12-18 2007-04-24 Hoffmann-La Roche Inc. Liposome compositions
US20100031378A1 (en) 2008-08-04 2010-02-04 Edwards Joel A Novel gene disruptions, compositions and methods relating thereto
US7713517B2 (en) 2004-04-21 2010-05-11 Marval Biosciences, Inc. Compositions and methods for enhancing contrast in imaging
US8357351B2 (en) 2004-04-21 2013-01-22 Ananth Annapragada Nano-scale contrast agents and methods of use
JP2008513533A (ja) 2004-09-23 2008-05-01 ゲルベ Ｃｅｓｔイメージング用の造影剤封入システム
WO2007119108A2 (en) 2005-10-13 2007-10-25 Waratah Pharmaceuticals Inc. Inositol derivatives and their uses in the treatment of diseases characterized by abnormal protein folding or aggregation or amyloid formation, deposition, accumulation or persistence
US20070160658A1 (en) 2005-10-20 2007-07-12 The Penn State Research Foundation Delivery system for diagnostic and therapeutic agents
US20090123047A1 (en) 2007-03-21 2009-05-14 Yfantis Spyros A Method and system for characterizing prostate images
EP1982733A1 (en) 2007-04-17 2008-10-22 Bayer Schering Pharma Aktiengesellschaft Use of a contrast agent for magnetic resonance imaging of endoleaks
US7858803B2 (en) 2007-04-27 2010-12-28 The General Hospital Corporation Imaging tracers for early detection and treatment of amyloid plaques caused by Alzheimer's disease and related disorders
US20110311457A1 (en) 2007-07-26 2011-12-22 Nanoscan Imaging, Llc Methods for imaging vascular inflammation using improved nanoparticle contrast agents
JP2011506325A (ja) 2007-12-05 2011-03-03 マーバル バイオサイエンシーズ インコーポレイテッド ナノスケールのコントラスト剤及びその使用方法
JP5647899B2 (ja) 2008-01-08 2015-01-07 ラツィオファルム ゲーエムベーハーｒａｔｉｏｐｈａｒｍ ＧｍｂＨ オリゴサッカリルトランスフェラーゼを使用するポリペプチドの複合糖質化
ITMI20081052A1 (it) 2008-06-10 2009-12-11 Univ Milano Bicocca Liposomi in grado di legare efficacemente il peptide beta-amiloide
US20090311191A1 (en) 2008-06-13 2009-12-17 Ananth Annapragada Imaging of atherosclerotic plaques using liposomal imaging agents
WO2010017094A2 (en) 2008-07-31 2010-02-11 The General Hospital Corporation CURCUMIN DERIVATIVES FOR AMYLOID-β PLAQUE IMAGING
AR074760A1 (es) * 2008-12-18 2011-02-09 Metabolex Inc Agonistas del receptor gpr120 y usos de los mismos en medicamentos para el tratamiento de diabetes y el sindrome metabolico.
AU2010226566A1 (en) 2009-03-19 2011-11-03 Board Of Regents Of The University Of Texas System Compositions and methods for enhancing contrast in imaging
EP2501696B1 (en) 2009-10-15 2016-12-28 Guerbet Imaging agents and their use for the diagnostic in vivo of neurodegenerative diseases, notably alzheimer's disease and derivative diseases
CA2801182A1 (en) 2010-06-16 2011-12-22 Metabolex, Inc. Gpr120 receptor agonists and uses thereof
ES2913069T3 (es) 2011-03-02 2022-05-31 Sensulin Llc Composiciones de vesículas
AU2012239888B9 (en) 2011-04-06 2017-10-12 Alzeca Biosciences, LLC Lipid-based nanoparticles
GB201112056D0 (en) * 2011-07-14 2011-08-31 Univ Leuven Kath Antibodies
JP6130401B2 (ja) 2012-01-20 2017-05-17 アンナプラガダ，アナンス 医学画像を客観的に特徴付けるための方法および組成物
US9377472B2 (en) * 2012-04-30 2016-06-28 Amoneta Diagnostics Biological complex specific for Alzheimer's disease detection in vitro and use thereof
MX2015011677A (es) * 2013-03-14 2016-07-08 Celtaxsys Inc Inhibidores de leucotrieno a4 hidrolasa.
KR102409017B1 (ko) 2014-10-08 2022-06-16 텍사스 칠드런스 하스피탈 리포좀을 이용한 아밀로이드 플라크의 mri 영상화

Similar Documents

Publication Publication Date Title
Wang et al. Manganese-based contrast agents for magnetic resonance imaging of liver tumors: Structure–activity relationships and lead candidate evaluation
TW319763B (enExample)
US11141495B2 (en) MRI imaging of amyloid plaque using liposomes
US8647604B2 (en) Lanthanide rich nanoparticles, and their investigative uses in MRI and related technologies
JP6212032B2 (ja) 脂質ベースのナノ粒子
CN108289970A (zh) 包含mri造影剂的组合的制剂
JP2014523854A5 (enExample)
JP7114074B2 (ja) 画像化のためのニトロキシドを含むアミロイド結合剤およびその治療的使用
Urbanovsky et al. Lanthanide complexes of DO3A–(Dibenzylamino) methylphosphinate: effect of Protonation of the Dibenzylamino Group on the water-exchange rate and the binding of human serum albumin
WO2010141704A2 (en) Imaging of myelin basic protein
CN1487947A (zh) 顺磁性金属-酞菁配位化合物和使用其的造影剂
Lucas et al. Comparison of a tartaric acid derived polymeric MRI contrast agent to a small molecule model chelate
KR102931218B1 (ko) 자기 공명 영상(MRI)에 의한 β-아밀로이드 플라크의 검출용 조영제로서 나프탈렌 유도체와 접합된 금속 산화물 나노입자
Pushparaj et al. Trinuclear Gd (III) metal complex with amide core display remarkable enhancement in relaxivity
JP4786112B2 (ja) 金属イオンキレート化錯体と共役させた胆汁酸誘導体の微小血管の診断評価のための使用
JP2022523056A5 (enExample)
Granato et al. Synthesis and relaxometric characterization of new Poly [N, N‐bis (3‐aminopropyl) glycine](PAPGly) Dendrons Gd‐based contrast agents and their in vivo study by using the dynamic contrast‐enhanced MRI technique at low field (1 T)
WO2007128567A1 (de) Verwendung von perfluoralkylhaltigen metallkomplexen als kontrastmittel zur diagnose der alzheimer krankheit
Chang et al. Dynamic contrast-enhanced magnetic resonance imaging evaluation of VX2 carcinoma in a rabbit model: comparison of 1.0-M gadobutrol and 0.5-M gadopentetate dimeglumine
Petiet et al. Improvement of microscopic MR imaging of amyloid plaques with targeting and non-targeting contrast agents
US20230022136A1 (en) Diffusivity contrast agents for medical imaging
Djanashvili et al. Responsive nanozeolites: Smart porosity and surface tailoring for multimodal imaging and therapy of cancer
Burke et al. Contrast enhancement of liver lesions in cirrhotic patients: a single institution crossover comparative study of two MR contrast agents. Preliminary results
KR101480393B1 (ko) 간암 진단을 위한 조영제용 가돌리늄 착물과 이를 이용한 간암 진단용 조영제
Fransen et al. r1 and r2 Relaxivities of Dendrons Based on a OEG‐DTPA Architecture: Effect of Gd3+ Placement and Dendron Functionalization